Skip to main content
main-content

Genitourinary cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews top story

Detection bias may contribute to reduced prostate cancer risk in diabetes

PSA test

The reduced prostate cancer risk seen in men with diabetes may be partly explained by detection bias due to a lower biopsy rate following an elevated prostate-specific antigen test result, population-based study data show.

medwireNews top story

Different ADT combination therapies offer similar prostate cancer survival benefits

Prostate cancer medicines

Adding docetaxel, abiraterone acetate, enzalutamide, or apalutamide to androgen deprivation therapy significantly improves survival for men with metastatic hormone-sensitive prostate cancer, with little difference between each drug, a network meta-analysis shows.

medwireNews top story

Network meta-analysis identifies best clinical choices for EGFR-mutated NSCLC

Pills_syringe

Osimertinib and gefitinib plus pemetrexed-based chemotherapy offer the best survival outcomes for patients with advanced EGFR-mutated non-small-cell lung cancer compared with other first-line treatments, shows a network meta-analysis of randomized trials.

07-10-2019 | Prostate cancer | Video | Article

Expert comment: The STAMPEDE study

Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).

07-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: A novel CXCR4 inhibitor for RCC and a novel immunotherapy endpoint

David McDermott talks through his renal cell carcinoma research exploring the use of a novel oral CXCR4 inhibitor and treatment-free survival as an alternative endpoint for immunotherapy trials (4:03).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

04-10-2019 | Renal cell carcinoma | Video | Article

Expert highlights: RCC immunotherapy at ESMO 2019

Axel Merseburger presents his round-up of the most interesting research on immunotherapy in renal cell carcinoma at the ESMO Congress 2019, including the TITAN RCC study and additional analyses from JAVELIN Renal 101 (3:14).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

04-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: Cabazitaxel a new third-line option in mCRPC

Ronald de Wit tells us why the CARD trial results are likely to change the paradigm for the treatment of metastatic castration-resistant prostate cancer (3:58).

03-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: PROfound improvement in outcomes with olaparib in mCRPC

The PROfound trial evaluated olaparib in metastatic castration-resistant prostate cancer ─ Maha Hussain discusses the clinical implications and practical applications of the findings (2:40).

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The CARD trial

Silke Gillessen comments on the phase IV CARD study investigating third-line cabazitaxel in men with metastatic castration-resistant prostate cancer (3:02). 

07-11-2019 | Prostate cancer | Highlight | News

Detection bias may contribute to reduced prostate cancer risk in diabetes

The reduced prostate cancer risk seen in men with diabetes may be partly explained by detection bias due to a lower biopsy rate following an elevated prostate-specific antigen test result, population-based study data show.

06-11-2019 | Castration-sensitive prostate cancer | Highlight | News

Different ADT combination therapies offer similar prostate cancer survival benefits

Adding docetaxel, abiraterone acetate, enzalutamide, or apalutamide to androgen deprivation therapy  significantly improves survival for men with metastatic hormone-sensitive prostate cancer, with little difference between each drug, a network meta-analysis shows.

04-11-2019 | Prostate cancer | News

Factors mediating statin prostate cancer protective effect identified

Statin use is associated with a reduced risk for low- and high-Gleason score prostate cancer, but the association is modified by the duration, dose, and type of statin, study results suggest.

31-10-2019 | Renal cell carcinoma | At a glance | Article

At a glance: The JAVELIN RCC trials

Reference

26-09-2019 | Renal cell carcinoma | At a glance | Article

At a glance: The KEYNOTE RCC trials

A quick-reference guide to the KEYNOTE clinical trials evaluating the immune checkpoint inhibitor pembrolizumab in patients with renal cell carcinoma.

31-10-2019 | Renal cell carcinoma | At a glance | Article

At a glance: The JAVELIN RCC trials

A quick-access guide to the JAVELIN trials of the anti-PD-L1 agent avelumab in the renal cell carcinoma setting.

Journal articles and book chapters

16-04-2019 | Renal cell carcinoma | Article

Towards individualized therapy for metastatic renal cell carcinoma

Kotecha RR et al. Nat Rev Clin Oncol 2019; 16(10): 621-633. doi:10.1038/s41571-019-0209-1.



26-03-2019 | Prostate cancer | Article

The role of multiparametric MRI in biopsy-naive prostate cancer

Lebastchi Ah, Pinto PA. Nat Rev Urol 2019; 16: 276–277. doi:10.1038/s41585-019-0173-7 

21-08-2018 | Prostate cancer | Article

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

Crawford ED, Heidenreich A, Lawrentschuk N et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0079-0.

Our Editorial Board advisor

Axel S Merseburger

Dr Merseburger is currently Professor and Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Dr Merseburger’s key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in German Phase II and III trials.

Image Credits